𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

✍ Scribed by Lajos Pusztai; Peter Wagner; Nuhad Ibrahim; Edgardo Rivera; Richard Theriault; Daniel Booser; Fraser W. Symmans; Franklin Wong; George Blumenschein; Donald R. Fleming; Roman Rouzier; Graeme Boniface; Gabriel N. Hortobagyi

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
183 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Paclitaxel-based second-line therapy for
Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1) : A clinical Phase II study
✍ Thomas Otto; Axel Bex; Susanne Krege; Peter H. Walz; Herbert RΓΌbben πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 2 views

and an antimotility factor (acellular pertussis vaccine [APV]) in 18 School, Essen, Germany. patients with cisplatin-and methotrexate-resistant metastatic bladder carcinoma. Intramuscular injection of APV 3 times in the first week, on Days 1, 4, and 7, was

A Phase II trial of high dose epirubicin
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
✍ Kathy D. Miller; Nikhil Munshi; David Loesch; Lawrence H. Einhorn; George W. Sle πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 3 views

## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Phase II study of daunorubicin in previo
Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma
✍ Harvey, J. ;Bonnem, E. ;Grady, K. ;Goodman, A. ;Schein, P. πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

Fourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR). The drug was administered at a dose of 15 mg/m2 on day 1 through 3 and 8 through 10. After a Cday rest period DNR was given in weekly injections of 15 mg/m2. There were no partial or comp